Back to News
Market Impact: 0.18
Leerink Partners Initiates Coverage of Nautilus Biotechnology with Outperform
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Leerink Partners initiated coverage of Nautilus Biotechnology (NASDAQCM: NAUT) with an Outperform rating on September 9, 2026. Shares had closed at $0.93 on September 8, up 0.15% over the prior week; the initiation is a modestly positive catalyst for the micro-cap biotech stock.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
NAUT0.45
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- Goldman says these top tech stocks have plenty of upside ahead of earnings
- ProPetro’s 49% decline: how Fair Value spotted the warning signs
- Persistent Oil Prices Threaten Inflation Outlook
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Could France’s debt crisis spread across Europe?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI in Asset Management: 2026 Statistics That Hold Up
- What is Broker Research and RMS Systems (And How to Actually Use Them)